Stay updated with breaking news from Ira Winer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of...
Milestone for Company’s lead peptide-drug conjugate candidate follows FDA acceptance of protocol amendment for Phase 1 study on June 2, 2023
/PRNewswire/ -- Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug...
/PRNewswire/ -- Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug...
Share this article TARRYTOWN, N.Y., May 19, 2021 /PRNewswire/ -- Presentations include first positive clinical data for the fianlimab (LAG-3 inhibitor) and Libtayo combination in advanced melanoma Regeneron will host an investor webcast on Monday, June 7 to provide further updates across its oncology portfolio Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the company will share a range of presentations for its PD-1 inhibitor Libtayo ® (cemiplimab-rwlc) and broader oncology portfolio at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8,...